Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8058067 | 0.85 | EDNRA (0.79) | EDNRACCR4 | |
| SCHEMBL8055624 | 0.84 | EDNRA (0.68) | EDNRACCR4 | |
| SCHEMBL1387322 | 0.80 | EDNRA (1.00) | EDNRACCR4 | |
| SCHEMBL8042519 | 0.78 | EDNRA (1.00) | EDNRACCR4 | |
| SCHEMBL1387437 | 0.78 | EDNRA (0.81) | EDNRACCR4 | |
| SCHEMBL8055603 | 0.78 | EDNRA (0.67) | EDNRACCR4 | |
| SCHEMBL8058031 | 0.78 | EDNRA (0.79) | EDNRACCR4 | |
| SCHEMBL8395496 | 0.77 | EDNRA (0.98) | EDNRACCR4 | |
| SCHEMBL8395498 | 0.77 | EDNRA (0.98) | EDNRACCR4 | |
| SCHEMBL6038923 | 0.77 | EDNRA (0.79) | EDNRACCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6083951-A | FOR THE TREATMENT OF DISEASES OR MEDICAL CONDITIONS SUCH AS HYPERTENSION, PULMONARY HYPERTENSION, CARDIAC OR CEREBRAL CIRCULATORY DISEASE AND RENAL DISEASE | ZENECA LIMITED (GB) | 2000-07-04 | — | — | US | disclosed |
| US-5861401-A | TREATMENT OF CONGESTIVE HEART FAILURE | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| EP-0752986-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026957-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1995-10-12 | — | — | WO | disclosed |